Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
MWN-AI** Summary
Clearmind Medicine Inc., a clinical-stage biotech firm listed on Nasdaq under the symbol "CMND," announced the publication of six innovative patents in Hong Kong on March 17, 2026. These patents pertain to novel combination therapies that utilize Palmitoylethanolamide (PEA), developed in partnership with NeuroThera Labs Inc., alongside notable psychedelic compounds such as MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT. The aim of these proprietary formulations is to enhance therapeutic outcomes, while simultaneously improving safety, tolerability, and neuroplasticity associated with a range of mental health and neurological disorders.
CEO Adi Zuloff-Shani emphasized the strategic importance of expanding the company's intellectual property (IP) portfolio to protect its pioneering approach in the field of psychedelic-based therapies. The incorporation of PEA with established psychedelics is geared towards developing next-generation therapeutic candidates that address significant unmet medical needs, particularly in mental health sectors.
Clearmind currently holds an extensive intellectual property portfolio, encompassing nineteen patent families and a total of 31 granted patents. The company remains proactive in seeking additional patent protections for its compounds and is open to acquiring further intellectual property to bolster its offerings.
The advancements underscore Clearmind’s commitment to pioneering research in psychedelic-derived therapeutics, addressing relevant issues including alcohol use disorder. The company's forward-looking statements reflect its aspirations to broaden its IP and develop innovative therapies, although actual outcomes may vary due to inherent risks associated with biotech developments.
For further engagement, stakeholders are encouraged to visit Clearmind's official site for more information on its ongoing initiatives and investment opportunities.
MWN-AI** Analysis
Clearmind Medicine Inc. (Nasdaq: CMND) has recently taken a significant step in its growth trajectory by announcing the publication of six innovative patents covering next-generation psychedelic-based combination therapies. This development underscores the company’s commitment to expanding its intellectual property portfolio, a crucial element for any biotech firm aimed at commercializing novel therapeutics.
The patents protect combinations of Palmitoylethanolamide (PEA) with established psychedelic compounds such as MDMA, LSD, and Psilocybin, enhancing the company's potential for addressing substantial unmet needs in mental health care. Given the growing acceptance and clinical interest surrounding psychedelics for treatment of various psychological ailments, Clearmind's innovations position it well in a burgeoning market.
Investors should take note of Clearmind's active partnership with NeuroThera Labs, which not only strengthens its pipeline through collaboration but also enhances credibility among stakeholders. The ongoing development of non-hallucinogenic compounds reflects a thoughtful approach to leveraging the therapeutic benefits of psychedelics while mitigating risks associated with traditional psychoactive substances.
From a market perspective, the current bullish trend in biotech—especially in sectors involving mental health treatments—presents a favorable backdrop for Clearmind. However, potential investors must remain cautious. While the patents provide a safeguard for the company’s innovations, the commercial viability of these therapies will ultimately depend on successful clinical trials and regulatory approvals.
The stock remains a speculation play; thus, a diversified portfolio approach is advisable when considering investment in Clearmind. Additionally, keeping an eye on the regulatory landscape and developments in psychedelic medicine will be crucial. Overall, Clearmind's advancements could lead to substantial long-term gains, but investors should weigh these opportunities against the inherent risks typical of clinical-stage biotech companies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, Canada, March 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of six patents by the Intellectual Property Department in Hong Kong. These patents cover proprietary combination therapies integrating Palmitoylethanolamide (PEA), sourced through the Company's partnership with NeuroThera Labs Inc. (TSXV: NTLX), with leading classic and innovative psychedelic compounds.
The published patents protect innovative synergistic formulations combining PEA with each of the following: 3,4-Methylenedioxymethamphetamine (MDMA), Lysergic Acid Diethylamide (LSD), Ketamine, Ibogaine, Psilocybin, and N,N-Dimethyltryptamine (DMT). These novel combinations aim to enhance therapeutic potential while potentially improving safety, tolerability, and neuroplasticity profiles for various mental health and neurological indications.
"We continue to expand our global IP portfolio and taking steps forward in protecting our innovative approach to psychedelic-based combination therapies," said Adi Zuloff-Shani, CEO of Clearmind Medicine. "By strategically combining PEA from our valued partners at NeuroThera with well-characterized psychedelics such as MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT, we continue to build a robust pipeline of next-generation candidates designed to address unmet needs in mental health and beyond.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses continuing to expand its global IP portfolio and taking steps forward in protecting its innovative approach to psychedelic-based combination therapies and continuing to build a robust pipeline of next-generation candidates designed to address unmet needs in mental health and beyond. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
How does Clearmind Medicine Inc. (CMND) plan to leverage its recent patent publication in Hong Kong to enhance its competitive positioning in the psychedelic therapeutics market?
Can you elaborate on how Clearmind Medicine Inc. (CMND) aims to address unmet mental health needs through its innovative combination therapies with Palmitoylethanolamide (PEA)?
What specific milestones does Clearmind Medicine Inc. (CMND) anticipate achieving in the next 12-24 months regarding its psychedelic-based pipeline and intellectual property expansion?
How does Clearmind Medicine Inc. (CMND) plan to mitigate the risks associated with its forward-looking statements and the uncertainties surrounding patent approvals in the evolving biotech landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
41.04% G/L:
$3.53 Last:
41,970,858 Volume:
$3.49 Open:
